Sign In
Buy PAVM
$4.68
-0.230 (-4.68%)
At Close: Jun 23, 2026
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025
08:31am, Thursday, 01'st May 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 1, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical techn
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
08:31am, Wednesday, 30'th Apr 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer preventio
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know
01:05pm, Monday, 28'th Apr 2025
PAVmed (PAVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
08:01am, Thursday, 24'th Apr 2025
Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK , April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
09:23am, Friday, 11'th Apr 2025
NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVm
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
07:24pm, Wednesday, 09'th Apr 2025
NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 09'th Apr 2025
NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
09:00am, Thursday, 03'rd Apr 2025
NEW YORK , April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed
Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK , March 27, 2025 /PRNewswire/ -- Lucid Diagnostics I
PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript
11:08am, Tuesday, 25'th Mar 2025
PAVmed Inc. (NASDAQ:PAVM ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Confe
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
08:01am, Tuesday, 25'th Mar 2025
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advanc
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
08:01am, Monday, 24'th Mar 2025
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concie
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
08:31am, Thursday, 20'th Mar 2025
Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK , March 20, 2025 /PRNewswi
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
08:31am, Tuesday, 18'th Mar 2025
Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , March 18, 2025 /PRNewswire/ -- Lucid Diagnosti
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
07:36am, Thursday, 13'th Mar 2025
Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancer NEW YORK , March 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"
